Hermann Esselmann
Overview
Explore the profile of Hermann Esselmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
1989
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Benson G, Bartels C, Stamatis F, Belz M, Esselmann H, Frolich L, et al.
Geriatrics (Basel)
. 2025 Feb;
10(1).
PMID: 39997520
: Mild cognitive impairment (MCI) is a heterogeneous clinical syndrome and is important for the diagnosis and management of Alzheimer's disease (AD). With the expansion of biomarker-based diagnostics, the aim...
2.
Itting P, Sadlonova M, Santander M, Knierim M, Derad C, Asendorf T, et al.
Int J Surg
. 2025 Feb;
PMID: 39903520
Background: Postoperative delirium (POD) is a severe complication following cardiac surgery and is associated with increased morbidity and mortality. The impact of intra- and early postoperative factors on the occurrence...
3.
Vogelgsang J, Hansen N, Stark M, Wagner M, Klafki H, Morgado B, et al.
Alzheimers Dement
. 2024 Jun;
20(8):5132-5142.
PMID: 38940303
Introduction: Blood-based biomarkers are a cost-effective and minimally invasive method for diagnosing the early and preclinical stages of amyloid positivity (AP). Our study aims to investigate our novel immunoprecipitation-immunoassay (IP-IA)...
4.
Soares Martins T, Ferreira M, Magalhaes S, Leandro K, Almeida L, Vogelgsang J, et al.
J Alzheimers Dis
. 2024 Mar;
98(3):1157-1167.
PMID: 38489187
Background: Alzheimer's disease (AD) diagnosis is difficult, and new accurate tools based on peripheral biofluids are urgently needed. Extracellular vesicles (EVs) emerged as a valuable source of biomarker profiles for...
5.
Soares Martins T, Pelech S, Ferreira M, Pinho B, Leandro K, de Almeida L, et al.
Int J Mol Sci
. 2024 Feb;
25(3).
PMID: 38338863
Phosphorylation plays a key role in Alzheimer's disease (AD) pathogenesis, impacting distinct processes such as amyloid-beta (Aβ) peptide production and tau phosphorylation. Impaired phosphorylation events contribute to senile plaques and...
6.
Morgado B, Klafki H, Bauer C, Waniek K, Esselmann H, Wirths O, et al.
Eur Arch Psychiatry Clin Neurosci
. 2024 Feb;
PMID: 38316685
The Aβ42/40 ratio and the concentration of phosphorylated Tau181 in blood plasma represent attractive biomarkers for Alzheimer's disease. As a means for reducing potential matrix effects, which may interfere with...
7.
Sadlonova M, Hansen N, Esselmann H, Celano C, Derad C, Asendorf T, et al.
Am J Geriatr Psychiatry
. 2024 Jan;
32(7):835-851.
PMID: 38228452
Objective: Postoperative delirium (POD) is a common complication of cardiac surgery that is associated with higher morbidity, longer hospital stay, cognitive decline, and mortality. Preoperative assessments may help to identify...
8.
Hermesdorf M, Esselmann H, Morgado B, Jahn-Brodmann A, Herrera-Rivero M, Wiltfang J, et al.
Brain Commun
. 2023 Oct;
5(5):fcad263.
PMID: 37901043
Blood-based analysis of amyloid-β is increasingly applied to incrementally establish diagnostic tests for Alzheimer's disease. To this aim, it is necessary to determine factors that can alter blood-based concentrations of...
9.
Klafki H, Wirths O, Jahn O, Morgado B, Esselmann H, Wiltfang J
Clin Chem Lab Med
. 2023 Sep;
62(2):e56-e57.
PMID: 37775501
No abstract available.
10.
Klafki H, Morgado B, Wirths O, Jahn O, Bauer C, Esselmann H, et al.
Fluids Barriers CNS
. 2022 Dec;
19(1):96.
PMID: 36461122
Background: A reduced amyloid-β (Aβ)42/40 peptide ratio in blood plasma represents a peripheral biomarker of the cerebral amyloid pathology observed in Alzheimer's disease brains. The magnitude of the measurable effect...